Key Enzymes Involved in Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia (CAH) is a group of genetic disorders affecting steroid production in the adrenal glands. These conditions result from hereditary enzyme deficiencies essential for the synthesis of cortisol and/or aldosterone. The main enzyme deficiencies responsible for CAH include:
- Severe deficiency of the 21-hydroxylase enzyme.
- Deficiency of the 17-hydroxylase enzyme.
- Insufficiency of 3β-hydroxysteroid dehydrogenase.
- Various partial and rare enzyme deficiencies.
The clinical manifestations observed in patients with CAH are highly variable and fundamentally depend on the specific enzyme that is absent or deficient, as well as the degree of residual enzymatic activity present in the individual.
21-Hydroxylase Deficiency: The Most Prevalent Form of CAH
21-hydroxylase is the most commonly affected enzyme, accounting for approximately 95% of all congenital adrenal hyperplasia diagnoses. This deficiency can manifest from the early neonatal period or remain latent until puberty or adulthood. Insufficiency of this enzyme causes a drop in cortisol production and, simultaneously, an increase in androgen production due to the shunting of precursors. Furthermore, about one-third of those affected suffer from inadequate aldosterone synthesis.
When the severe form of 21-hydroxylase deficiency is established in the first two weeks of life, it can trigger a «salt-wasting» crisis—essentially, severe acute adrenal insufficiency—. In the case of females born with the condition, genital ambiguity is observed at birth. Mild or partial enzyme variants have a more moderate clinical course, typically manifesting later with clear signs of androgen excess.
| Clinical Presentation Associated with 21-Hydroxylase Deficiency |
| Acute Adrenal Insufficiency Crisis |
- Direct result of low cortisol production along with aldosterone deficiency.
- Common symptoms: persistent vomiting, significant dehydration, and marked hypotension.
- Presents with an intense desire to ingest salt (salt craving).
|
| Genital Ambiguity in the Newborn |
- Caused by the excessive accumulation of prenatal androgens.
- Affects only female patients (causing female pseudohermaphroditism).
- Typical presentation: significant enlargement of the clitoris, with potential partial or total fusion of the labia majora.
- The external genitalia may resemble typically masculine structures.
|
| Late-Onset Manifestations in Women |
- Progressive virilization: deeper voice, limited breast development, increased muscle mass, and elevated libido.
- Accelerated skeletal maturation (acceleration of bone age).
- Menstrual irregularities or amenorrhea (absence of periods).
- Increased growth of body hair following a male pattern (hirsutism).
- Seborrheic skin and resistant acne.
- Possible development of androgenetic alopecia.
|
| Late-Onset Manifestations in Men |
- Precocious pubertal development (precocious puberty).
- Increased rate of bone maturation.
- Testicular enlargement due to the growth of ectopic adrenal tissue within the testicular parenchyma.
|
Diagnostic Process for 21-Hydroxylase Deficiency
Accurate diagnosis of the enzyme deficiency requires a methodical approach, starting with the clinical evaluation of hormonal symptoms. Definitive confirmation is based on specific biochemical tests.
Diagnosis and Management of Congenital Adrenal Hyperplasia (CAH)
The diagnosis of Congenital Adrenal Hyperplasia (CAH) should be considered in any infant presenting signs of severe adrenal insufficiency, virilization (in the case of female newborns), or precocious puberty (in males).
Initial analyses, requested when acute adrenal insufficiency is suspected, will reveal the salt-wasting status, which is characterized by the following electrolyte imbalances:
- Low serum sodium (hyponatremia).
- Elevated serum potassium (hyperkalemia).
- Low serum aldosterone levels.
- Decreased serum cortisol concentrations.
- Elevated plasma renin activity.
To specifically confirm 21-hydroxylase deficiency, the commonly affected enzyme, measuring the elevation of the following hormones in blood or urine samples is required:
- 17-hydroxyprogesterone in serum.
- DHEA sulfate in plasma.
- Pregnanetriol in urine.
- 17-ketosteroids measured in urine.
If a newborn's genitals present morphological abnormalities, an adrenal ultrasound examination may be necessary. Additionally, advanced genetic testing is available to precisely identify the specific mutation responsible for the condition.
Prenatal Diagnostic Evaluation
When fetal risk is known because a previous sibling has been diagnosed with CAH, genetic testing can be considered during gestation to assess the health of the developing fetus.
Ensuring early identification of the deficient enzyme is fundamental for implementing adequate management of congenital adrenal hyperplasia, as treatment varies substantially depending on the underlying cause and the severity of the hormonal dysfunction.
This diagnostic scenario is confirmed if both parents carry the genetic abnormality predisposition. The available prenatal diagnostic tools include:
- Chorionic villus sampling, being the recommended procedure starting from the eighth week of gestation.
- Amniocentesis, which is usually performed near the twelfth week of gestation.
Likewise, a definitive diagnosis can be obtained if elevated concentrations of 17-hydroxyprogesterone are detected in the amniotic fluid, fluid, usually around the 14th week of gestation.
Treatment of Classic Congenital Adrenal Hyperplasia
The therapeutic management of the classic form of CAH is focused on counteracting exaggerated ACTH secretion through the administration of glucocorticoid replacement (cortisol). This is usually achieved with a low dose of dexamethasone, specifically 0.5 mg administered at night.
To effectively reduce excessive circulating androgen levels, anti-androgen therapy can be incorporated. Pharmacological agents commonly used in these cases include:
- Cyproterone acetate
- Spironolactone
- Flutamide
- Finasteride
In the specific subtype involving salt wasting, administering a mineralocorticoid, normally fludrocortisone (at a standard dose of 0.1 mg), is a fundamental pillar of treatment. The goal is to maintain adequate extracellular fluid volume and stabilize electrolyte levels. Treatment adherence and efficacy are periodically monitored by checking blood pressure, serum electrolytes, and plasma renin activity.
Identification and Therapy for 17-Hydroxylase Deficiency
17-hydroxylase deficiency represents an infrequent pathological entity that tends to manifest during the pubertal stage, due to reduced production of adrenal androgens, which causes hypogonadism..
- In individuals with a female phenotype, significant pubertal delay is observed, manifested by primary amenorrhea and absence of breast or pubic development.
- In individuals with a male phenotype, ambiguous external genitalia or a predominantly female external appearance are present (known as male pseudohermaphroditism).
This enzyme deficiency results in decreased cortisol synthesis and, concurrently, an increase in mineralocorticoid levels. Distinctive analytical findings include:
- Elevated blood pressure (hypertension).
- Low serum potassium concentrations (hypokalemia).
- Reduced plasma renin levels.
- Low levels of 17-ketosteroids excreted in the urine.
- Elevated urinary gonadotropin concentrations.
The primary therapeutic approach consists of administering dexamethasone to control associated hypertension and providing exogenous testosterone to facilitate appropriate sexual development and maturation.
Comprehensive Understanding of 3β-Hydroxysteroid Dehydrogenase Deficiency
Deficiency of the 3β-hydroxysteroid dehydrogenase enzyme represents a significant endocrine disorder that obstructs the production of all vital steroid hormones generated in the adrenal glands, including cortisol, aldosterone, androgens, and estrogens.
This pathological condition usually manifests acutely during early childhood, presenting critical symptoms such as recurrent episodes of vomiting, severe salt loss (salt-wasting crisis), and, in the case of genetically predisposed newborns, genital ambiguity.
Biochemical analyses are crucial for diagnosis and typically reveal a distinctive pattern:
- Low serum sodium levels.
- Elevated potassium concentrations (hyperkalemia).
- A marked increase in urinary DHEA excretion.
- Decrease in minimal urinary cortisol metabolites, specifically 17-hydroxycorticosteroids.
Pathophysiological Mechanism of Enzymatic Blockade
The core of the problem lies in the alteration of the essential enzymatic conversion of pregnenolone to progesterone. This metabolic blockade is responsible for curtailing the . Although pure cysteamine has a characteristic sulfurous odor, the cream developers indicate that they have significantly mitigated this drawback through innovative technology. adequate synthesis of both cortisol and aldosterone. As a direct consequence of this insufficiency, a relative and unbalanced accumulation of lower-potency adrenal androgens occurs.
In the female sex, this androgen excess results in varying degrees of partial virilization, affecting secondary sexual development. For males, the deficiency in testicular testosterone production caused by this enzymatic defect can lead to incomplete or atypical formation of the external male genitalia.
Therapeutic Strategies for Steroid Insufficiency
The management of 3β-hydroxysteroid dehydrogenase deficiency demands a comprehensive, lifelong therapeutic plan. This treatment must include glucocorticoid replacement therapy to compensate for cortisol deficiency and fludrocortisone supplements to maintain electrolyte balance through aldosterone replacement.
Furthermore, it is imperative to administer appropriate sex steroids for the individual's sex genetic sex, starting administration as soon as the pubertal stage is reached to ensure physical and secondary sexual development aligns with expectations.
